[go: up one dir, main page]

DK3287140T3 - Nervevækstfaktorsammensætning og pulverinjektion - Google Patents

Nervevækstfaktorsammensætning og pulverinjektion Download PDF

Info

Publication number
DK3287140T3
DK3287140T3 DK16782601.5T DK16782601T DK3287140T3 DK 3287140 T3 DK3287140 T3 DK 3287140T3 DK 16782601 T DK16782601 T DK 16782601T DK 3287140 T3 DK3287140 T3 DK 3287140T3
Authority
DK
Denmark
Prior art keywords
growth factor
nerve growth
powder injection
factor composition
composition
Prior art date
Application number
DK16782601.5T
Other languages
English (en)
Inventor
Jianping Tan
Bingzhang Wang
Original Assignee
Beijing Staidson Medical Tech Co Ltd
Staidson Beijing Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57144485&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3287140(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beijing Staidson Medical Tech Co Ltd, Staidson Beijing Biopharmaceuticals Co Ltd filed Critical Beijing Staidson Medical Tech Co Ltd
Application granted granted Critical
Publication of DK3287140T3 publication Critical patent/DK3287140T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16782601.5T 2015-04-21 2016-04-18 Nervevækstfaktorsammensætning og pulverinjektion DK3287140T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510189156 2015-04-21
PCT/CN2016/079571 WO2016169454A1 (zh) 2015-04-21 2016-04-18 一种神经生长因子组合物及注射粉剂

Publications (1)

Publication Number Publication Date
DK3287140T3 true DK3287140T3 (da) 2021-07-19

Family

ID=57144485

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16782601.5T DK3287140T3 (da) 2015-04-21 2016-04-18 Nervevækstfaktorsammensætning og pulverinjektion

Country Status (6)

Country Link
US (1) US11077193B2 (da)
EP (1) EP3287140B1 (da)
CN (1) CN107660149B (da)
DK (1) DK3287140T3 (da)
ES (1) ES2882106T3 (da)
WO (1) WO2016169454A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114642729B (zh) * 2020-12-21 2023-12-15 舒泰神(北京)生物制药股份有限公司 一种凝血因子x激活剂组合物
CN114177273B (zh) * 2021-11-29 2024-05-28 苏州人本药业有限公司 一种含有神经毒素的液体制剂及其制备方法
CN119258198A (zh) * 2023-07-07 2025-01-07 重庆科润生物医药研发有限公司 一种含重组人神经生长因子的组合物及其应用和眼用制剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6277828B1 (en) * 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
DK1516628T3 (da) 1995-07-27 2013-09-08 Genentech Inc Stabil, isotonisk lyofiliseret proteinformulering
US6090781A (en) 1996-11-06 2000-07-18 Genentech, Inc. Stabilizing formulation for NGF
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6663899B2 (en) * 1997-06-13 2003-12-16 Genentech, Inc. Controlled release microencapsulated NGF formulation
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
JP4317010B2 (ja) 2001-07-25 2009-08-19 ピーディーエル バイオファーマ,インコーポレイティド IgG抗体の安定な凍結乾燥医薬製剤
ES2377959T3 (es) 2002-05-03 2012-04-03 Novo Nordisk Health Care Ag Composiciones sólidas estabilizadas de factor VII modificado
CN1318087C (zh) * 2003-06-06 2007-05-30 北京三诺佳邑生物技术有限责任公司 去白蛋白神经生长因子制剂
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
WO2006014965A2 (en) 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
KR20110022096A (ko) * 2005-12-20 2011-03-04 주식회사 삼양사 고분자 마이크로스피어의 제조 방법 및 제조 장치
CN1824297A (zh) * 2005-12-30 2006-08-30 安徽金大陆生物制药有限公司 神经生长因子制品在制备治疗视神经病变药物中的应用
CN1843503A (zh) 2006-01-25 2006-10-11 安徽金大陆生物制药有限公司 一种滴眼剂
CN1857718A (zh) * 2006-03-22 2006-11-08 安徽金大陆生物制药有限公司 一种神经生长因子注射剂
TW200831129A (en) 2006-10-06 2008-08-01 Amgen Inc Stable formulations
AU2008255016B2 (en) 2007-05-15 2013-05-09 Stryker Corporation Concentrated protein preparations of bone morphogenetic proteins and methods of use thereof
CN101461786A (zh) * 2009-01-08 2009-06-24 上海交通大学 用水包油-油包固体制备的pla/plga壳-核微球及其制备方法
CN101972470B (zh) 2010-09-13 2012-10-17 舒泰神(北京)生物制药股份有限公司 一种眼用原位凝胶
CN101972224B (zh) * 2010-09-13 2012-01-04 舒泰神(北京)生物制药股份有限公司 一种眼用原位凝胶
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
FR3011836B1 (fr) * 2013-10-10 2015-10-23 Saint Gobain Vitrage de controle thermique

Also Published As

Publication number Publication date
EP3287140B1 (en) 2021-06-02
WO2016169454A1 (zh) 2016-10-27
EP3287140A4 (en) 2018-12-26
US11077193B2 (en) 2021-08-03
EP3287140A1 (en) 2018-02-28
CN107660149B (zh) 2021-04-27
CN107660149A (zh) 2018-02-02
US20180161436A1 (en) 2018-06-14
ES2882106T3 (es) 2021-12-01

Similar Documents

Publication Publication Date Title
ZA201805065B (en) Hair growth composition and method
GB2546350B (en) Compositions and methods
ZA201802125B (en) Pharmaceutical composition and application thereof
EP3302442C0 (en) DOSAGE FORMS AND THEIR USE
DK3169741T3 (da) Forbedrede bindemiddelsammensætninger og anvendelser deraf
DK3169733T3 (da) Forbedrede bindemiddelsammensætninger og anvendelser deraf
DK3319428T3 (da) Herbicid sammensætning omfattende cinmethylin og imazamox
ZA201608046B (en) Pesticidal compositions and related methods
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3102200T3 (da) Terapeutisk forbindelse og sammensætning
GB201718876D0 (en) Antithrombin-heparin compositions and methods
IL253538A0 (en) Heterocyclic compound and pharmaceutical compound containing it
ZA201703398B (en) Pharmaceutical composition and methods
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
DK3590523T3 (da) Vækstfremmende peptider og anvendelser deraf
GB201502268D0 (en) Dental composition and use
DK3287140T3 (da) Nervevækstfaktorsammensætning og pulverinjektion
SI3349594T1 (sl) Sestavek nadomestka soli in uporaba le-tega
DK3166960T3 (da) Lav-substituerede polymyxiner og sammensætninger deraf
GB201512996D0 (en) Compositions and methods
IL248863A0 (en) Preparations containing il-31 and their use
DK3287139T3 (da) Nervevækstfaktorsammensætning og injektionspulver
DK3287141T3 (da) Nervevækstfaktorsammensætning og injektionspulver
GB201401706D0 (en) Nanoparticle-insulin and insulin analogue compositions
ZA201801745B (en) Biocides and preparation thereof